| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Glial Fibrillary Acidic Protein (GFAP)
Test Code14319
CPT Codes
83520
Preferred Specimen
0.7 mL plasma collected in an EDTA (lavender-top) tube
Patient Preparation
Patients should be cautioned to stop biotin consumption at least 72 hours prior to collection of a sample
Minimum Volume
0.5 mL
Other Acceptable Specimens
Serum
Instructions
Draw blood in EDTA (lavender-top) tube (invert to mix with preservatives) or serum separator tube or red-top tube (no gel). Centrifuge and transfer plasma or serum to a labeled plastic transport tube. Specify sample type collected on tube.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 43 days
Refrigerated: 43 days
Frozen: 40 days
Refrigerated: 43 days
Frozen: 40 days
Methodology
Electrochemiluminescence Immunoassay
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Tues-Sat; Report available: 1-3 days
Clinical Significance
Glial fibrillary acidic protein (GFAP) is a protein expressed in astrocytes, cells that support neurons and help form the blood-brain barrier, found within the central nervous system (CNS) and is involved in several important CNS processes. It is a marker of astrogliosis and is upregulated in the brain as a result of attempts at repair and the formation of a glial scar. Glial scarring occurs as a result of several neurodegenerative processes, including Alzheimer's disease, multiple sclerosis, and neuromyelitis optica. It can also be seen after damaging pathological events such as traumatic brain injury and stroke [1]. Increased presence of GFAP can also be observed in association with brain tumors such as glioblastoma multiforme [2]. GFAP expression is known to decrease in disorders such as schizophrenia, bipolar disorder, and depression [3].
1. Nature Reviews Neurology 18(3):158-172.
2. J Neuro Sci 35 (1):147-155.
3. Molecular Psychiatry 5(2):142-149.
1. Nature Reviews Neurology 18(3):158-172.
2. J Neuro Sci 35 (1):147-155.
3. Molecular Psychiatry 5(2):142-149.

